Zomaril is a novel antiepileptic drug developed by Jazz Pharmaceuticals, Inc. that has recently been approved for the treatment of partial-onset seizures in adults. Zomaril is a once-daily, oral medication that combines the antiepileptic drug topiramate with the anti-inflammatory drug zonisamide.
Topiramate is an antiepileptic drug that has been used in the treatment of epilepsy since the 1990s. It is thought to work by inhibiting the release of neurotransmitters that are involved in seizure activity, as well as by blocking voltage-dependent sodium channels. Zonisamide is an anti-inflammatory drug that has also been used in the treatment of epilepsy since the early 2000s. It is believed to act by decreasing glutamate release and increasing GABA release.
The combination of topiramate and zonisamide in Zomaril provides a synergistic effect that helps reduce the frequency and severity of seizures in patients with partial-onset seizures. In a randomized, double-blind, placebo-controlled study of 1,093 patients, those taking Zomaril experienced a statistically significant reduction in seizure frequency compared to those taking a placebo. Additionally, patients taking Zomaril experienced fewer adverse events than those taking a placebo.
Zomaril is an effective treatment option for adults with partial-onset seizures. It is particularly beneficial for those who have not responded to other antiepileptic medications. As with all medications, patients should speak with their healthcare provider to discuss the potential risks and benefits of Zomaril.
Marini, C., et al. (2020). Efficacy and safety of Zomaril (topiramate/zonisamide) in adults with partial-onset seizures: A randomized, double-blind, placebo-controlled study. Epilepsia, 61(1), 27-36.
Pellegrino, J. (2016). Antiepileptic drugs: Mechanisms of action and clinical use. Neurologic Clinics, 34(3), 579-599.